0

Meningioma - A Pipeline Analysis Report

  • Published: Jul 2018
  • Pages: 71
  • SKU: IRTNTR23396
Technavio

The 2022-2026 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted
  • 2500.00
  • USD

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for meningioma including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, and target.

Overview of the drug development for meningioma

Meningioma is a tumor that arises from the meninges, membranes that surround the brain and the spinal cord. Although it is no exactly a brain tumor, it is included in this category because it may compress or squeeze the adjacent brain tissues, nerves, and vessels. It is most common type of tumor that forms in the head. Most meningiomas grow very slowly, often over many years, without causing symptoms. But in some cases, their effects on the adjacent brain tissues, nerves, or vessels may cause serious consequences. Since most of the meningiomas grow slowly, they do not always require immediate treatment and can be monitored over time.  The number of cancer registries worldwide that recorded malignant brain tumors is less, and there are concerns regarding the accuracy of the recorded data. A surge in the incidences of primary brain tumors in general and of meningiomas specifically has been registered in many countries during the past decades. It is said that the main reasons for this surge could be the aging population, better access to advanced healthcare facilities and diagnostic procedures, and the changes in coding classification for the meningiomas registered. As a result, the increasing number of instances of the disease have further boosted the drug development for meningioma.

According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for meningioma. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of meningioma. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

  • AstraZeneca
  • Eli Lilly
  • Merck Sharp & Dohme
  • Novartis
  • Pfizer

Therapeutic assessment of the drug development for meningioma by route of administration

  • Oral
  • Intravenous
  • Intramuscular

The oral route of administration (ROA) involves the application of the drug directly into the mouth cavity, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development for meningioma by targets

  • PD-1
  • CDK4 and CDK6
  • mTORC1/mTORC2
  • MEK1/MEK2
  • RTK
  • NMDA receptor
  • PP2A
  • DNA
  • PDL1
  • Somatostatin receptor

According to this pipeline analysis report, most of the molecules that are currently in the drug development for meningioma are being developed on PD-1 targets and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

  • What are the drug molecules in the various development stages for meningioma?
  • What are the companies that are currently involved in the development of drug molecules for meningioma?
  • Insight into discontinued/inactive molecules with appropriate reasoning?
  • What are the major regulatory authorities approving drugs in various regions?
  • Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.

 

Read More Read Less

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

PART 05: MAJOR REGULATORY AUTHORITIES

  • US
  • Europe
  • China

PART 06: PIPELINE LANDSCAPE

PART 07: COMPARATIVE ANALYSIS

  • Discovery stage molecules
  • Pre-clinical stage molecules
  • Inactive and discontinued molecules

PART 08: INDICATION ANALYSIS

PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)

PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)

PART 11: THERAPEUTIC ASSESSMENT BY TARGET

PART 12: KEY COMPANIES

  • Active companies: Category and parameters

PART 13: APPENDIX

  • List of abbreviations

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

TechnavioINFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases
Technavio

TechnavioDATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts
Technavio

TechnavioREPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your FREE sample now!
Safe and Secure SSL Encrypted
Technavio

Single User:

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer $1000 worth of FREE customization at the time of purchase
Technavio
Enquire Before Buying
  1. Home
  2. Health Care
  3. Published Report
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>